| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/12/2006 | EP1644335A1 Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| 04/12/2006 | EP1644332A1 Diarylmethyl derivatives as potassium channel modulators |
| 04/12/2006 | EP1644330A2 Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids |
| 04/12/2006 | EP1644323A2 Histone deacetylase inhibitors and methods of use thereof |
| 04/12/2006 | EP1644318A1 New method for synthesizing ceramide-type compounds |
| 04/12/2006 | EP1644086A1 Use of whey permeate for the treatment of metabolic syndrome |
| 04/12/2006 | EP1644047A2 Delivery of a drug via subconjuctival or periocular delivery of a prodrug in a polymeric microparticle |
| 04/12/2006 | EP1644042A1 A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate |
| 04/12/2006 | EP1644041A1 A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine |
| 04/12/2006 | EP1644038A2 Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis |
| 04/12/2006 | EP1644026A2 Sigma ligands for neuronal regeneration and functional recovery |
| 04/12/2006 | EP1644024A2 Antimicrobial flush solutions |
| 04/12/2006 | EP1644020A2 Lyase treatment for p. carinii |
| 04/12/2006 | EP1644019A1 Abuse resistant amphetamine compounds |
| 04/12/2006 | EP1644014A1 Combinations of vasoactive agents and their use in the treatment of sexual dysfunctions |
| 04/12/2006 | EP1644013A1 Processes for making caralluma extracts and uses |
| 04/12/2006 | EP1644012A1 Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in manufacture of medicaments |
| 04/12/2006 | EP1644009A2 Compositions and methods for increasing telomerase activity |
| 04/12/2006 | EP1644008A2 Continuous dosing regimen with abt-751 |
| 04/12/2006 | EP1644007A1 Composition comprising one or more phytosterols and/or phytostanols and glucomannan and uses of the composition in treating lipid disorders in individuals with and without type ii diabetes |
| 04/12/2006 | EP1644006A1 Pharmaceutical composition for the treatment and/or the prevention of atherosclerosis from infectious origin |
| 04/12/2006 | EP1644005A1 Metabolite of quetiapine |
| 04/12/2006 | EP1644004A2 Tropical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions |
| 04/12/2006 | EP1644003A1 Triazolo ´1,5-a!pyrimidines and their use in medicine |
| 04/12/2006 | EP1644002A1 Multiparticulates |
| 04/12/2006 | EP1644001A2 Pancratistatin cyclic phosphate prodrugs an phenpanstatin cyclic phosphate prodrugs |
| 04/12/2006 | EP1644000A1 Compositions containing a serotonin selective reuptake inhibitor and a 5-ht2a receptor antagonist |
| 04/12/2006 | EP1643999A1 Pyridoxamine for the treatment of diabetic kidney disease |
| 04/12/2006 | EP1643998A1 Dual nk1/nk3 antagonists for treating schizophrenia |
| 04/12/2006 | EP1643997A1 Flupirtine preparation for treating neurodegenerative disorders of the visual system and diabetes mellitus |
| 04/12/2006 | EP1643996A1 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| 04/12/2006 | EP1643995A1 Treatment of migraine accompanied by nausea |
| 04/12/2006 | EP1643994A2 Methods for inhibiting or reversing tau filament fibrillization |
| 04/12/2006 | EP1643993A2 Substituted isochroman compounds for the treatment of metabolic disorders, cancer and other diseases |
| 04/12/2006 | EP1643990A1 Metronidazole-based green tinted topical pharmaceutical composition |
| 04/12/2006 | EP1643986A2 Phenylcarboxylate beta-secretase inhibitors for the treatment of alzheimer s disease |
| 04/12/2006 | EP1643985A1 The combination of a serotonin reuptake inhibitors and agomelatine |
| 04/12/2006 | EP1643984A2 Use of parthenolide derivatives as antileukemic and cytotoxic agents |
| 04/12/2006 | EP1643983A2 Methods of inhibiting vascular permeability and apoptosis |
| 04/12/2006 | EP1643982A2 Method of treating acute myocardial infarction |
| 04/12/2006 | EP1643981A2 Antiviral compositions and methods of using the same |
| 04/12/2006 | EP1643980A1 Dry powder for inhalation comprising a formoterol salt and ciclesonide |
| 04/12/2006 | EP1643978A1 Parathyroid hormone (pth) containing pharmaceutical compositions for oral use |
| 04/12/2006 | EP1643976A2 Pharmaceutical formulation comprising levothyroxine sodium |
| 04/12/2006 | EP1643975A2 Process for preparing formulations of lipid-regulating drugs |
| 04/12/2006 | EP1643974A1 Inhalable pharmaceutical formulations comprising a sugar ester |
| 04/12/2006 | EP1643972A1 Stabilized topotecan liposomal composition and methods |
| 04/12/2006 | EP1643969A2 Compositions and methods for hydrophobic drug delivery |
| 04/12/2006 | EP1643965A2 Protection against sunburn and skin problems with orally-ingested high-dosage zeaxanthin |
| 04/12/2006 | EP1643961A2 Cox-2 and faah inhibitors |
| 04/12/2006 | EP1643960A2 Arylsulfonamide derivatives |
| 04/12/2006 | EP1643958A2 Method for selective targeting of apoptotic cells and small molecule ligands used thereof |
| 04/12/2006 | EP1643947A2 Delivery system for topical medications |
| 04/12/2006 | EP1643865A1 Nutritional compositions and use thereof |
| 04/12/2006 | EP1643864A1 Aiding of cognitive function |
| 04/12/2006 | EP1643863A2 Foods, beverages, condiments, spices and salad dressings with specialized supplements |
| 04/12/2006 | EP1643862A1 Infant formula |
| 04/12/2006 | EP1643846A1 Method for treatment of sores and lesions of the skin |
| 04/12/2006 | EP1643836A1 Arylmethyl triazolo and imidazopyrazines as c-met inhibitors |
| 04/12/2006 | EP1643835A2 CONTROL OF PROTOZOA AND PROTOZOAN CYSTS THAT HARBOR iLEGIONELLA |
| 04/12/2006 | EP1562447A4 Antioxidative compositions |
| 04/12/2006 | EP1560826B1 Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same |
| 04/12/2006 | EP1556380B1 Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, preparation thereof and application of same in therapeutics |
| 04/12/2006 | EP1549647B1 Substituted c-imidazo¬1,2-a|pyridin-3-yl-methylamines |
| 04/12/2006 | EP1546151B1 Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans |
| 04/12/2006 | EP1542988B1 Piperidine quinolyl propyl derivatives, preparation method and intermediates and compositions containing same |
| 04/12/2006 | EP1511747B1 Imidazo-pyridine derivatives as ligands for gaba receptors |
| 04/12/2006 | EP1476444B1 Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy |
| 04/12/2006 | EP1446403B1 Aryl substituted oxazolidinones with antibacterial activity |
| 04/12/2006 | EP1423436B1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids |
| 04/12/2006 | EP1414433B1 Improved pharmaceutical composition containing a ppar alpha agent and a process for preparing it |
| 04/12/2006 | EP1409513B1 Methylene-4-azasteroids |
| 04/12/2006 | EP1409101B1 Formation of small crystals |
| 04/12/2006 | EP1404671B1 Macrocycles useful in the treatment of alzheimer's disease |
| 04/12/2006 | EP1404174A4 Anti-infective compositions for treating disordered tissue such as cold sores |
| 04/12/2006 | EP1401828B1 N-formyl hydroxylamine compounds as inhibitors of pdf |
| 04/12/2006 | EP1389213B1 3,7-diazabicyclo 3.3.1| formulations as antiarhythmic compounds |
| 04/12/2006 | EP1385858B1 Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof |
| 04/12/2006 | EP1358183B1 Cysteine protease inhibitors |
| 04/12/2006 | EP1355639B1 Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists |
| 04/12/2006 | EP1345920B1 Novel sulfamides and their use as endothelin receptor antagonists |
| 04/12/2006 | EP1343771B1 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen c-proteinase inhibitors |
| 04/12/2006 | EP1336605B1 Substituted phenol derivatives or salts thereof as inhibitors of coagulation factor x |
| 04/12/2006 | EP1317272B1 Composition for improving the cell protection comprising a lipophilic antioxidant an a hydrophilic antioxidant |
| 04/12/2006 | EP1311499B1 Bicyclic compounds as h3 receptor ligands |
| 04/12/2006 | EP1311471B1 Phenyl- and phenylalkyl-substituted ethanolamines and ethylenediamines |
| 04/12/2006 | EP1299089B1 Drug delivery system for poorly water soluble drugs |
| 04/12/2006 | EP1294368A4 Management of snoring by oral administration of dimethyl sulfone |
| 04/12/2006 | EP1270017B1 Radiolabeled pyrimidine nucleoside for the diagnosis of tissue-reproductive activity |
| 04/12/2006 | EP1254119B1 Pyrimidine derivatives as selective inhibitors of cox-2 |
| 04/12/2006 | EP1233767B1 Pyruvate ester composition and method of use for resuscitation after events of ischemia and reperfusion |
| 04/12/2006 | EP1207873A4 Methods of inhibiting osteoclast activity |
| 04/12/2006 | EP1202639B1 Method for suppressing appetite |
| 04/12/2006 | EP1200040B1 Two-component composition for cosmetic or pharmaceutical use |
| 04/12/2006 | EP1194156B1 Dietary supplement for treating malignancies and viral infections and improving immune function |
| 04/12/2006 | EP1192247B1 Sphingosine kinase enzyme |
| 04/12/2006 | EP1191922B1 Composition based on fluorinated polymer and alpha-hydroxy-acid salt for topical use for skin protection |
| 04/12/2006 | EP1146851B1 Galenic formulation containing biotin |
| 04/12/2006 | EP1118659B1 Expression systems for functional nucleic acid expression |
| 04/12/2006 | EP1087981B1 Prenyl transferase inhibitors |